anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including Ibuprofen Tablets. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice, fulminant hepatitis, liver necrosis, and hepatic failure, some of them with fatal outcomes have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver test values, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with Ibuprofen Tablets. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), Ibuprofen Tablets should be discontinued.
Procedure to obtain a laeation for dental amalgamas. Consists in heating in an electric fusion oven of vacuum of starting product containing ag, sn, cu and zn, until its fusion, which is then passed to a cooling mold, which is cooled between 15 and 50 c ./h. In a second phase it goes to a homogenized oven, where it remains at a temperature of 400 to 470 c. For approximately 10 hours. The allocation obtained is subjected to a phase of molding through a lathe and a mortar until the product has a granulometry comprised between 0.4 and 0.006 mm. The process finishes a thermal treatment against tensions in elective oven in a controlled atmosphere. (Machine-translation by Google Translate, not legally binding)
The present invention relates to one-particularly-moisture perspiration-absorbent cosmetic product, such as, a kind of reodorant containing a suction sweat mixture. The present invention also relates to and a kind of produces described mixture and the method for described cosmetic product. Cosmetic product in the present invention comprises i) a kind of base formulation, and ii) a kind of suction sweat mixture, comprise (a) at least one absorbent composition, (b) at least one tensio-active agent, (c) at least one electrolytic solution, and (d) at least one solvent and/or at least one carrier. Suction sweat mixture in base formulation exists with emulsified particle form. This particle is made up of with at least partly by described at least one tensio-active agent bag quilt the water absorption and swelling three-dimensional network of a described at least one absorbent composition. Described at least one electrolytic solution is mixed in the network polymer space of described at least one absorbent composition.
PURPOSE:To obtain a composition, containing fluoride ions, calcium ions, a substance capable of promoting colloidizing of a reaction product between both the ingredients and a nonionic water-soluble polymer, capable of improving the fluorine intake by teeth and excellent in anticarious effects. CONSTITUTION:A composition for the oral cavity is obtained by including (A) a water-soluble fluoride (e.g. sodium fluoride), (B) a water-soluble calcium salt, e.g. a chloride or a glycerophosphate, (C) a substance capable of promoting colloidizing of the ingredients (A) and (B), e.g. a 3-10C monosaccharide having one or two or more phosphate groups and/or sulfate groups and/or carboxyl groups in the molecule and an oligosacccharide in which 2-6 above-mentioned monosaccharides are bonded and (D) a nonionic water-soluble polymer, e.g. hydroxyalkyl celluloses or alginic acid esters. The respective ingredients are preferably blended at (0.1-10):1:(0.05-20) ratio of F ions : Ca ions : ingredient (C) and the content of the F is preferably 150-60000ppm. The amount of the ingredient (D) is preferably 0.05-5wt.% (based on the total amount of the composition).
A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
Fibroblasts are essential for building and maintaining the structural integrity of all organs. Moreover, fibroblasts can acquire an inflammatory phenotype to accommodate immune cells in specific niches and to provide migration, differentiation, and growth factors. In the heart, balancing of fibroblast activity is critical for cardiac homeostasis and optimal organ function during inflammation. Fibroblasts sustain cardiac homeostasis by generating local niche environments that support housekeeping functions and by actively engaging in intercellular cross talk. During inflammatory perturbations, cardiac fibroblasts rapidly switch to an inflammatory state and actively communicate with infiltrating immune cells to orchestrate immune cell migration and activity. Here, we summarize the current knowledge on the molecular landscape of cardiac fibroblasts, focusing on their dual role in promoting tissue homeostasis and modulating immune cell-cardiomyocyte interaction. In addition, we discuss potential future avenues for manipulating cardiac fibroblast activity during myocardial inflammation.
A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. Methods according to the present invention are particularly useful in treating peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.
Multiple myeloma (MM) is a hematological malignant tumor characterized by clonal proliferation of abnormal plasma cells in the bone marrow. The incidence of MM is mainly in the middle and old age, and the incidence of MM in China has increased in recent years. At present, MM is still an incurable disease in general, and the vast majority of patients will eventually face disease recurrence or progression. Recurrent or refractory MM is still a thorny problem in the treatment of MM, which is an important factor for the survival of patients.Although CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM, for MM patients with BCMA negative or BCMA low expression, they still relapse after receiving targeted BCMA CAR T-cell therapy, and there is a problem of target escape. The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM. This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM.
The invention discloses a drug for curing female infertility caused by poor smooth flow of a fallopian tube, relates to the technical field of drugs, and in particularly to a drug for curing the female infertility. The drug for curing the female infertility caused by the poor smooth flow of the fallopian tube comprises, by weight, 15 g of angelica sinensis, 15 g of roots of red-rooted salvia, 15 g of fried rhizoma corydalis, 15 g of roots of common peony, 15 g of nutgrass galingale rhizome, 15 g of lumbricus, 15 g of beautiful sweetgum fruit, 15 g of fried dipsacus roots, 15 g of rhizoma cibotii, 15 g of motherwort fruit, 20 g of herba leonuri, 10 g of roots of three-nerved spicebush, 10 g of pericarpium citri reticulatae viride, 10 g of dried tangerine, 10 g of dried fructus aurantii, 10 g of turmeric, 10 g of Sichuan thorn seeds, 10 g of rhizoma sparganii, 10 g of curcuma zedoary, and 5 g of elecampane. According to a preparation method of the drug for curing the female infertility caused by the poor smooth flow of the fallopian tube, all the raw materials are prepared into particles or capsules according to by means of a conventional method of Chinese materia medica preparation. The dose of the drug for curing the female infertility caused by he poor smooth flow of the fallopian tube is about 50 g of the raw materials, and the drug is taken three times per day. A patient takes the drug from the first day of a menstrual period, and continuously takes the drug for four days, and then stops taking the drug for eight days, and then begin to take the drug from the thirteenth day for three days, and stops taking the drug for seven days, and then continue to take the drug from the twenty-third day for three days, and a course of treatment is achieved. The drug for curing the female infertility caused by the poor smooth flow of the fallopian tube is capable of curing the infertility of females getting married for more than three years and the infertility caused by the poor smooth flow of the fallopian tube, and has the functions of regulating menstruation, nourishing bodies, enriching blood, and relieving stasis.
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to development of homeopathic drug that can be used for treatment of patients with parasitic cholecystitis. Composition consists of Artemisia vulgaris, Chenopodium anthelminticum, Tanacetum vulgare, Juglans regia taken at equal ratio at the following dilutions: Artemisia vulgaris D3, Chenopodium anthelminticum D3, Tanacetum vulgare D3, Juglans regia C12. Composition is the homeopathic drug as sugar granules. Agent promotes to recovery of body adaptogenic response due to interaddition and enhancement of complex effect of its components. EFFECT: enhanced effectiveness of agent. 2 cl, 1 ex
Hepatic ischemia/reperfusion (I/R) damage is one of the most common side effects of liver surgery. This pathophysiological process may lead to excessive hepatic damage. Aloperine is an active ingredient isolated from Sophora alopecuroides Linn and has a variety of therapeutic effects, including organ protection. However, the hepatoprotective effect of aloperine against hepatic I/R damage has not yet been determined. C57BL/6 mice were allocated to the sham-operated (sham), hepatic ischemia/reperfusion (I/R), and aloperine groups. The mice were exposed to 30 min of hepatic hilum occlusion. Then a 3-h reperfusion was performed. Mice in the sham group underwent sham surgery. Hepatic injury was evaluated by plasma aspartate aminotransferase (AST) and transaminase alanine aminotransferase (ALT) levels, histological evaluation, cell apoptosis, the number of activated inflammatory cells, and the expression levels of inflammatory cytokines, including tumor necrosis factor-α and interleukin-6. The protein phosphorylation status of the reperfusion-associated survival pathways was evaluated. Mice with hepatic I/R injury presented increased plasma ALT and AST levels, increased hepatic apoptosis, abnormal histological structure, and elevated inflammatory responses. However, aloperine ameliorated hepatic I/R-induced injury. Moreover, aloperine enhanced the level of signal transducer and activator of transcription (STAT)-3 phosphorylation after I/R. Ag490, an agent that inhibits STAT-3 activity, abolished aloperine-induced STAT-3 phosphorylation and liver protection. Aloperine ameliorates hepatic I/R-induced liver injury via a STAT-3-mediated protective mechanism. Patients with hepatic I/R injury may benefit from aloperine treatment. SIGNIFICANCE STATEMENT: Hepatic I/R can cause excessive liver damage. This study revealed that aloperine, an active component isolated from Sophora alopecuroides Linn, ameliorates hepatic I/R injury and related liver damage in vivo. The underlying protective mechanism may involve the STAT-3 signaling pathway. These findings may lead to the development of a novel approach for treating hepatic I/R damage in clinical practice.
The invention discloses application of cyano-pyrridine compounds to prepare anti-HIV-1 medicines. The general formula of the compounds is shown in the specification. In the general formula, R is H or a C1-C4 alkane, and X is S or O. By utilizing the interaction of Vif-APOBEC3G, the compounds with the above general formula, especially ethyl 5-cyano-6-thioxo-1,6-dihydropyridine-2-carboxylate is confirmed to be capable of inhibiting the activity of Vif protein on degrading A3G and leading rising up of expression level of green fluorescent protein in a screening system. By performing wild-type HIV-1 infection experiments on human primary CD4+T lymphocyte and H9, SupT1 and other CD4+T lymphocytic series, ethyl 5-cyano-6-thioxo-1,6-dihydropyridine-2-carboxylate is further confirmed to have relatively good antiviral effect. A powerful theoretical basis and a practice basis are provided for further research and development of antiviral medicines, and the compounds have important value on research and development and exploitation meaning.
The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding GBA protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of GBA protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of GBA protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing GBA protein. Such GBA protein can be expressed for treating disease, e.g., Gaucher disease.
PURPOSE:To obtain a nucleated tablet, which has no defectives such as cracks without reducing a weight of nucleus tablet, by applying a construction of holding two nucleus tablets formed beforehand within that tablet formed by compressing a powder. CONSTITUTION:A nucleated tablet 1, which is oblate spheroidal and almost barrel- shaped, holds two nucleus tablets 3, which have been formed into a small oblate barrel- shape beforehand. That tablet 1 is prepared as follows. A powder 7, which is supplied from a powder inlet nozzle 18 into a pit of a large number of mortars 5 arranged on a circumference of a rotating disk 4, is filled in a fixed quantity by the first feed shoe 6, two nucleus tablets 3 are supplied on the powder by a nucleus supply instrument 8, and the second powder 7 is further filled into that mortar pit in a fixed quantity by the second feed shoe 9 after the supply of the nucleus tablets 3 is detected, memorized, etc. by an identification sensor 19. Then, the powder is compressed and formed by making an upper and a lower stamps pass through compression rolls 10, and a non-defective article is taken out and stored through a chute 20 into a receiver can 22 by a take-out damper 17. It is possible, therefore, not only to form a wall thickness of cover large but also to make a rate of wall thickness change small, resulting in a prevention of occurrences of defectives due to cracks.
Subjects will game for 2 hours sitting with no break. All subjects will undergo blood flow assessments without wearing lower leg graduated compression gear or taking an active break during their gaming session (i.e. during uninterrupted sitting).
A topical Chinese medicinal composition for treating alopecia areata: compound gamboge alopecia areata hair-growing tincture. The invention belongs to the technical field of external use of traditional Chinese medicines, and provides an external traditional Chinese medicine compound gamboge alopecia areata hair-growing tincture for treating alopecia areata, which is prepared from the following traditional Chinese medicine raw materials: 20-30 g of gamboge, 10-20 g of coptis chinensis and 1 g of borneol, soaking the gamboge in 500ml of 75% alcohol for 5-7 days, and removing residues to obtain tincture. Has the characteristics of simple preparation method, convenient use, excellent physical properties and the like. Can fasten hair root, activate dormant hair follicle, stop hair loss and promote hair growth, and is suitable for treating acute and chronic alopecia areata caused by various reasons. All patients have good compliance in the treatment period, no adverse reaction is found, and the drug is a safe and effective external drug for alopecia areata. Is suitable for large and medium-sized hospitals, basic sanitary units and folk self-supply. The medicine is a new medicine which is worth widely recommending and has good application value.
OBJECTIVES: Cardiotoxic chemotherapy is used to treat malignancies such as breast cancer and lymphoma. These treatments predispose patients to cardiotoxicity that can lead to cancer treatment-related cardiac dysfunction (CTRCD). The use of high doses of anthracyclines or in combination with human epidermal growth factor receptor 2 antagonists is associated with a progressively higher risk of CTRCD. CTRCD is preceded by increased activation of the sympathetic nervous system and abnormal left ventricular mechanical deformation as measured by abnormal global longitudinal strain (GLS). Low-level tragus stimulation (LLTS) is a new, safe, noninvasive technique that offers great potential to reduce increased sympathetic activation and improve GLS. Here, we describe a study method to examine the effects of LLTS on autonomic balance and cardiac function in breast cancer or lymphoma patients treated with anthracyclines.
METHODS: A first-in-human pilot, randomized, double-blind feasibility study will evaluate 104 patients (age >50 y) with breast cancer or lymphoma who receive anthracyclines with one additional CTRCD risk factor. Patients undergo 2 weeks of LLTS daily (1 h/d). Autonomic balance will be measured using heart rate variability metrics. Strain imaging using GLS will be performed pre and post-LLTS. Endothelial inflammation and oxidative stress measures will be performed using in vitro assays at baseline and after 2 weeks.
CONCLUSION: We hypothesize that LLTS stabilizes sympathovagal imbalance and improves cardiac performance in anthracycline-treated patients with breast cancer or lymphoma.
BACKGROUND: Acute pulmonary embolism (PE) is a serious condition that needs quick and effective treatment. Anticoagulation therapy is the usual care for most PE patients but may not work well for higher-risk ones. Thrombolysis breaks the clot and improves blood flow. It can be given systemically or locally. Ultrasound-assisted catheter-directed thrombolysis (USAT) is a new technique that boosts clot-busting drugs. This network meta-analysis compares death, bleeding, and benefits of four treatments in acute submassive PE.
METHODS: We comprehensively searched relevant databases up to July 2023 for RCTs. The outcomes encompassed all-cause mortality, major and minor bleeding, PE recurrence, and hospital stay duration. Bayesian network meta-analysis computed odds ratios (OR) and 95 % CI estimates.
RESULTS: In this network meta-analysis of 23 RCTs involving 2521 PE patients, we found that SCDT had the most favorable performance for mortality, as it had the lowest odds ratio (OR) among the four interventions (OR 5.41e-42; 95 % CI, 5.68e-97, 1.37e-07). USAT had the worst performance for major bleeding, as it had the highest OR among the four interventions (OR 4.73e+04; 95 % CI, 1.65, 9.16e+13). SCDT also had the best performance for minor bleeding, as it had the lowest OR among the four interventions (OR 5.68e-11; 95 % CI, 4.97e-25, 0.386).
CONCLUSION: Our meta-analysis suggests that SCDT is the most effective treatment intervention in improving the risks of All-cause mortality and bleeding. Thrombolytic therapy helps in improving endpoints including the risk of PE recurrence and the duration of hospital stay.
The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0\~pI esophageal squamous cell carcinoma and pII\~pIV esophageal squamous cell carcinoma by using DNA methylation detection technology. The differences in genomic methylation levels between different groups were compared to identify the methylolation site system associated with early esophageal squamous cell carcinoma. Then, using the genomic methylolation technique, 5hmC-DNA enrichment was performed on the peripheral venous blood samples of the experimental group before surgery and the peripheral venous blood samples of the control group, respectively, and then the high abundance and high significance were selected. The 5hmC-DNA fragment was verified by PCR amplification. The genes related to esophageal squamous cell carcinoma were verified by ctDNA methylolation. Finally, the methylolation genes related to esophageal squamous cell carcinoma were identified, and the application of DNA methylation in early screening of esophageal squamous cell carcinoma was explored.